Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
Stopped early
Conditions studied: Neuroblastoma
In brief
The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.
Key facts
- Study ID
- NCT04753658
- Run by
- Pfizer
- People needed
- 15
- Starts
- 2021-03-19
- Expected to finish
- 2022-09-30
- Last updated by the study team
- 2024-09-23
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
- HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
You may not qualify if…
- Any patient who does not meet any of the inclusion criteria defined in the previous section.
Where it is running
- University of Pennsylvania School of Medicine — Philadelphia, Pennsylvania, United States
- Westmead Hospital — Westmead, New South Wales, Australia
- ST0683AU - Chris O'Brien Lifehouse — Camperdown, New South Wales, 2050 Australia, Australia
- Starship Blood and Cancer Centre — Auckland, New Zealand
- Instituto Portugues de Oncologia de Lisboa — Lisbon, Portugal
- Seoul National University Bundang Hospital — Seongnam, South Korea
- Samsung Medical Center — Seoul, South Korea
- Queen Silvia Children's Hospital — Gothenburg, Sweden
- HRH Crown Princess Victoria's Children and Youth Hospital — Linköping, Sweden
- Karolinska Institutet — Stockholm, Sweden
- Norrland University Hospital — Umeå, Sweden
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.